Brought to you by 
Servier licenses Alantos' Phase I diabetes candidate
23 Apr 2007
Executive Summary
Alantos Pharmaceuticals (small-molecule drugs for osteoarthritis, inflammation, and Type II diabetes) licensed Servier exclusive worldwide rights (except in the US, where Alantos retains rights) to develop and commercialize its Phase I ALS20426 for Type II diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier licenses Alantos' Phase I diabetes candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice